Xtant Medical Holdings, Inc.

Partnership leverages BioHorizons' commercial network to broaden availability of Xtant's allogeneic growth factor technology, OsteoFactor Pro™, which BioHorizons will private brand as Prolifica™ BELGRADE, Mont., Aug. 27, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and wound care disorders, announced an exclusive partnership with BioHorizons (a Henry Schein, Inc. company), whereby BioHorizons will distribute Xtant's allogeneic growth factor technology under the private brand Prolifica™ through its commercial network.

Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript

Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to host investor conference call and webcast today, August 11 th, at 8:30am ET BELGRADE, Mont., Aug. 11, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today reported financial and operating results for the second quarter ended June 30, 2026.

BELGRADE, Mont., Aug. 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for the second quarter ended June 30, 2026, before the start of trading on Tuesday, August 11, 2026.